Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Bosutinib

2

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

2
Last update : 25/09/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Dasatinib
4
Imatinib
3
Nilotinib
2

Publications

Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 Mar;29;511-516 2023 Mar
Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.
Clinical case reports 2021 May;9;e03164 2021 May
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
American journal of hematology 2014 Jul;89;732-42 2014 Jul
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Therapeutic advances in hematology 2014 Feb;5;13-7 2014 Feb
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood 2011 Oct 27;118;4567-76 2011 Oct 27

Powered by

  • ^
  • Contact
  • Cookies
  • About